Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 51 of 151

  1. EDP-938 Dose 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  2. EDP-938, EDP-938 Placebo tablets

    ENANTA PHARMACEUTICALS INC

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial

  3. EFAVIRENZ

    The George Institute

    Type C Niemann-Pick Disease

    phase 2 small molecule active

    1 trial

  4. EG-70 (phase 1)

    Shanghai Antengene Corporation Limited

    Superficial Bladder Cancer

    phase 2 small molecule active

    1 trial

  5. EG-70-101

    Shanghai Antengene Corporation Limited

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  6. EGFR Antibody

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  7. EGFR-TK Inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nonsmall Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. EIK1001

    Eikon Therapeutics

    NSCLC

    phase 2 small molecule active

    1 trial

  9. EIK1001-008

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  10. EIK1003-001

    Eikon Therapeutics

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  11. EIK1004 20mg Tablets, EIK1004 5mg Tablets

    Eikon Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  12. EIK1004-001 (IMP1707-001)

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  13. EIK1005

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  14. EIK1005-002

    Eikon Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  15. ELA-0121

    Stemline Therapeutics B.V.

    Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  16. ELACESTRANT

    Fondazione Telethon ETS

    Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)

    phase 2 small molecule active

    1 trial

  17. ELI-002 7P

    Elicio Therapeutics

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. ELRANATAMAB

    Pfizer Australia Pty Ltd

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  19. ELVN-002-003

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  20. ELX-02

    Eloxx Pharmaceuticals

    Alport Syndrome

    phase 2 small molecule completed

    1 trial

  21. ELX-02

    Eloxx Pharmaceuticals

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  22. ELX-02

    Eloxx Pharmaceuticals

    Genetic Disease

    phase 2 small molecule terminated

    2 trials

  23. EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    2 trials

  24. EMB-01

    Shanghai University of Traditional Chinese Medicine

    Neoplasms

    phase 2 small molecule active

    1 trial

  25. EMBRACE

    The George Institute

    SEPSIS

    phase 2 small molecule active

    1 trial

  26. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  27. ENDORET-PRGF

    The George Institute

    glaucoma

    phase 2 small molecule active

    1 trial

  28. ENGIC 01-COLOSOTO

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  29. ENHANCE

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  30. ENMD-2076

    CASI Pharmaceuticals

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  31. ENMD-2076

    CASI Pharmaceuticals

    Advanced Adult Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  32. ENMD-2076

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  33. ENTR-601-44

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  34. ENTR-601-44, SODIUM CHLORIDE

    Entrada Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  35. ENTR-601-45

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  36. EOF5

    Fudan University

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  37. EORTC 1612-MG

    Ningbo Cancer Hospital

    BRAF V600 mutation–positive unresectable or metastatic melanoma

    phase 2 small molecule active

    1 trial

  38. EORTC 1740-HNCG

    Ningbo Cancer Hospital

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  39. EORTC 2334-BTG

    Ningbo Cancer Hospital

    Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)

    phase 2 small molecule active

    1 trial

  40. EORTC-1745-ETF-BCG

    Ningbo Cancer Hospital

    Localized ER+ breast cancer

    phase 2 small molecule active

    1 trial

  41. EP-005

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial

  42. EP-104GI

    EUPRAXIA PHARMACEUTICALS INC.

    Eosinophilic Esophagitis

    phase 2 small molecule active

    1 trial

  43. EP-104IAR 25 mg

    EUPRAXIA PHARMACEUTICALS INC.

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial

  44. EP-262-201

    Lacuna Pharma Pty Ltd

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  45. EP0042-101

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 2 small molecule active

    1 trial

  46. EP0062-101

    Lacuna Pharma Pty Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  47. EPCORITAMAB, RITUXIMAB

    Daiichi Sankyo

    Hematological Malignancies

    phase 2 small molecule active

    1 trial

  48. EPI-321

    Biotech Pharmaceutical Co.,

    Facioscapulohumeral Muscular Dystrophy

    phase 2 mab active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.